Todisco Joseph's most recent trade in Talphera Inc. was a trade of 38,381 Director Stock Option (right to buy) done . Disclosure was reported to the exchange on Oct. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Talphera Inc | Joseph Todisco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2025 | 38,381 | 38,381 | - | - | Director Stock Option (right to buy) | |
| Talphera Inc | Joseph Todisco | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2025 | 6,397 | 6,397 (0%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Joseph Todisco | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 12 Sep 2025 | 50,000 | 509,496 (1%) | 0% | 13 | 650,000 | Common Stock |
| CorMedix Inc | Joseph Todisco | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.47 per share. | 12 Sep 2025 | 50,000 | 559,496 (2%) | 0% | 3.5 | 173,500 | Common Stock |
| CorMedix Inc | Joseph Todisco | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2025 | 50,000 | 216,667 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Joseph Todisco | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.66 per share. | 10 May 2025 | 21,225 | 509,496 (1%) | 0% | 11.7 | 247,484 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 01 Apr 2025 | 59,170 | 530,721 (2%) | 0% | 3.4 | 199,995 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 59,170 | 440,830 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 187,500 | 495,528 (1%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.17 per share. | 17 Jan 2025 | 23,977 | 471,551 (1%) | 0% | 12.2 | 291,800 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share. | 10 Jan 2025 | 17,829 | 308,028 (1%) | 0% | 11.2 | 199,507 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.17 per share. | 10 May 2024 | 26,982 | 325,857 (1%) | 0% | 5.2 | 139,497 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.74 per share. | 13 Mar 2024 | 13,561 | 352,839 (1%) | 0% | 3.7 | 50,718 | Common Stock |
| CorMedix Inc | Todisco Joseph | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 266,667 | 266,667 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Todisco Joseph | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 133,333 | 353,059 (1%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.47 per share. | 12 Jan 2024 | 13,781 | 339,278 (1%) | 0% | 3.5 | 47,820 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.58 per share. | 17 May 2023 | 5,000 | 209,726 (0%) | 0% | 4.6 | 22,900 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.30 per share. | 10 May 2023 | 37,443 | 204,726 (0%) | 0% | 5.3 | 198,448 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2023 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.82 per share. | 15 Nov 2022 | 20,000 | 242,169 (0%) | 0% | 3.8 | 76,400 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.92 per share. | 24 Aug 2022 | 4,700 | 222,169 (0%) | 0% | 3.9 | 18,424 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.38 per share. | 16 May 2022 | 10,000 | 217,469 (0%) | 0% | 3.4 | 33,800 | Common Stock |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Joseph Todisco | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 207,469 | 207,469 (0%) | 0% | 0 | Common Stock | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2022 | 4,442 | 328,756 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2022 | 4,442 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 07 May 2022 | 1,562 | 327,194 (0%) | 0% | 3.4 | 5,311 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 289,856 | 289,856 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 144,928 | 144,928 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 26,544 | 333,645 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 26,544 | 79,634 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 11,111 | 11,111 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 11,111 | 311,007 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.45 per share. | 01 Mar 2022 | 9,331 | 324,314 (0%) | 0% | 4.5 | 41,523 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.45 per share. | 01 Mar 2022 | 3,906 | 307,101 (0%) | 0% | 4.5 | 17,382 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2022 | 29,684 | 59,367 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2022 | 29,684 | 311,003 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.59 per share. | 27 Feb 2022 | 11,107 | 299,896 (0%) | 0% | 4.6 | 50,981 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Sale of securities on an exchange or to another person at price $ 4.10 per share. | 02 Dec 2021 | 1,500 | 281,319 (0%) | 0% | 4.1 | 6,150 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 4,441 | 284,381 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 4,441 | 4,442 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.20 per share. | 07 May 2021 | 1,562 | 282,819 (0%) | 0% | 5.2 | 8,122 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.75 per share. | 15 Mar 2021 | 36,330 | 316,270 (0%) | 0% | 2.8 | 99,908 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Sale of securities on an exchange or to another person at price $ 6.82 per share. | 15 Mar 2021 | 36,330 | 279,940 (0%) | 0% | 6.8 | 247,865 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 36,330 | 36,331 | - | - | Stock Option (Right to Buy) | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 212,356 | 212,356 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 106,178 | 106,178 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 29,683 | 89,051 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 29,683 | 283,707 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 11,111 | 283,846 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 11,111 | 22,222 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.39 per share. | 27 Feb 2021 | 10,972 | 272,735 (0%) | 0% | 5.4 | 59,139 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Joseph Todisco | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.18 per share. | 27 Feb 2021 | 3,906 | 279,940 (0%) | 0% | 5.2 | 20,233 | Class A Common Stock |